



TransIT[®]-BrCa Transfection Reagent

The first reagent designed and optimized for breast cancer cell lines

- **Broad Spectrum DNA Delivery** - Achieve high expression levels in multiple breast cancer cell types.
- **Formulated for Low Cellular Toxicity** - Maintain cell density and reduce experimental biases due to toxicity.
- **Superior Transfection Efficiency** - *TransIT[®]-BrCa* outperforms Lipofectamine[®] 2000 in numerous breast cancer cell lines.

TransIT[®]-BrCa Transfection Reagent
Yields High Efficiency Plasmid DNA
Transfection in Breast Cancer Cell Lines.





TransIT®-BrCa Transfection Reagent Exhibits Higher Luciferase Expression in Breast Cancer Cells Compared to Other Transfection Reagents. Breast cancer cell lines were transfected with a luciferase expression plasmid at the reagent-to-DNA ratios indicated. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression was measured at 24 hours post-transfection using a standard assay. Error bars represent the standard deviation of triplicate wells.

TransIT®-BrCa Transfection Reagent



PRODUCT NO.	QUANTITY
MIR5504	0.4 ml
MIR5500	1 ml
MIR5505	5 x 1 ml
MIR5506	10 x 1 ml

© 2017 All rights reserved. Mirus Bio LLC.
Mirus Bio and TransIT are registered trademarks of Mirus Bio LLC. Reagent Agent is a service mark of Mirus Bio LLC.
FuGENE® is a registered trademark of Fugent LLC. Lipofectamine® is a registered trademark of Life Technologies Corporation

© 2016 Thermo Fisher Scientific Inc. All rights reserved.
Trademarks used are owned as indicated at www.fishersci.com/trademarks.

In the United States:
For customer service, call 1-800-766-7000
To fax an order, use 1-800-926-1166
To order online: www.fishersci.com



A Thermo Fisher Scientific Brand

BN0109178